Screener
Axsome Therapeutics AXSM Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Total liabilities | 659,020 | 601,510 |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value per share (10,000,000 shares authorized, none issued and outstanding) | — | — |
| Common stock, $0.0001 par value per share (150,000,000 shares authorized, 51,420,445 and 50,882,766 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively) | 5 | 5 |
| Additional paid-in capital | 1,425,085 | 1,394,251 |
| Accumulated deficit | (1,370,503) | (1,305,961) |
| Total stockholders’ equity | 54,587 | 88,295 |
| Total liabilities and stockholders’ equity | $713,607 | $689,805 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's total equity?
- Axsome Therapeutics (AXSM) reported total equity of $54.59M in Q1 2026.
- How has Axsome Therapeutics's total equity changed year-over-year?
- Axsome Therapeutics's total equity increased by 2.6% year-over-year, from $53.21M to $54.59M.
- What is the long-term trend for Axsome Therapeutics's total equity?
- Over 5 years (2020 to 2025), Axsome Therapeutics's total equity has grown at a -4.9% compound annual growth rate (CAGR), from $113.79M to $88.3M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Axsome Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude